Our case reports an advanced EGFR‐mutant lung adenocarcinoma patient achieved PR and a PFS of 6 months to a combination of immunotherapy and anti‐angiogenic agent, sintilimab and bevacizumab, as subsequent‐line therapy. Here, EGFR is linked to lung adenocarcinoma.